Related Experiment Video

Updated: Jul 16, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Novel small-molecule inhibitors of the vascular endothelial growth factor receptor

Alex A Adjei1

  • 1Roswell Park Cancer Institute, Buffalo, NY 14263, USA. alex.adjei@roswellpark.org

Clinical Lung Cancer
|March 27, 2007
PubMed

Insights

Angiogenesis, crucial for cancer growth, is targeted by therapies blocking vascular endothelial growth factor (VEGF). This review covers small-molecule inhibitors of VEGF receptors in clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Sustained angiogenesis is a key characteristic of cancer development.
  • Vascular Endothelial Growth Factor (VEGF) plays a vital role in promoting blood vessel formation.
  • Therapeutic strategies targeting VEGF signaling are crucial in cancer treatment.

Purpose of the Study:

  • To review the development and clinical trial status of small-molecule inhibitors targeting VEGF receptors.
  • To discuss the mechanisms of action for these targeted therapies.
  • To provide an overview of current therapeutic approaches in inhibiting VEGF signaling.

Main Methods:

  • Review of scientific literature and clinical trial data.
  • Analysis of small-molecule inhibitors targeting VEGF receptor tyrosine kinase activity.
  • Discussion of therapeutic strategies including monoclonal antibodies and small-molecule inhibitors.

Main Results:

  • Several small-molecule inhibitors targeting VEGF receptors are currently in clinical trials.
  • These inhibitors represent a significant therapeutic approach to block VEGF signaling.
  • Monoclonal antibodies and small-molecule inhibitors are the two main strategies for VEGF inhibition.

Conclusions:

  • Small-molecule inhibitors of VEGF receptors are a promising area of cancer therapy.
  • Targeting VEGF signaling remains a critical focus in the development of anti-cancer drugs.
  • Ongoing clinical trials will determine the efficacy and safety of these novel inhibitors.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: